🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06977373
Starting soon Not applicable

The Application Value of Spectral CT in the Accurate Staging of Colorectal Cancer

NCT06977373 · tracked via the Priya Life Science China tracker
Sponsor
Yunnan Cancer Hospital
Phase
Not applicable
Started
2025-06-01
Last updated
2025-05-18

Condition(s) studied

Colorectal Cancer

Investigational drug(s) / intervention(s)

To explore the value of spectral CT in the diagnosis and treatment of colorectal cancer

To explore the value of spectral CT in the diagnosis and treatment of colorectal cancer: The CT scan is part of the standard treatment protocol.

Study summary

Spectral CT was used to prospectively collect medical images and clinical data related to colorectal cancer, evaluate the effect of image quality in the diagnosis of colorectal cancer, and evaluate the application value in the accurate staging of colorectal cancer, so as to provide a more accurate clinical basis for diagnosis, promote the development of individualized treatment, and ultimately improve the prognosis of patients.

Eligibility

Sex
ALL
Min age
18 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria: 1. Undergo a contrast-enhanced Quark Spectral CT scan of the lower abdomen/pelvis within 1 week before treatment. 2. Age \> 18 years. 3. Patients suspected of having colorectal cancer. 4. Patients who have signed the informed consent form. Exclusion Criteria: 1. Severe cardiac, pulmonary, or renal insufficiency. 2. Allergy to iodine-based contrast agents. 3. Inability to cooperate with the CT examination. 4. Poor image quality of the Quark Spectral CT scan. 5. Women who are pregnant or breastfeeding.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Yunnan Cancer Hospital Kunming City

More Yunnan Cancer Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06977373 on ClinicalTrials.gov ↗ ← All trials in China